Clinical Trials
3 trialsNCT05703516 2026-06-01
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Novartis
Recruiting
NCT04575025 2025-09-15
Special Drug Use-results Surveillance of Tabrecta Tablets
Novartis
Completed
NCT05675683 2023-01-09
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
Novartis
Completed